|
1
|
Nakasu Y, Mitsuya K, Hayashi N, Okamura I,
Mori K, Enami T, Tatara R, Nakasu S and Ikeda T: Response-adapted
treatment with upfront high-dose chemotherapy followed by
autologous stem-cell transplantation rescue or consolidation phase
high-dose methotrexate for primary central nervous system lymphoma:
a long-term mono-center study. Springerplus. 5:3072016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Szyska M and Na IK: Bone marrow GvHD after
allogeneic hematopoietic stem cell transplantation. Front Immunol.
7:1182016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bortin MM: A compendium of reported human
bone marrow transplants. Transplantation. 9:571–587. 1970.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Passweg JR, Baldomero H, Bader P, Bonini
C, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH,
Farge-Bancel D, et al: European Society for Blood and Marrow
Transplantation (EBMT): Hematopoietic SCT in Europe 2013: recent
trends in the use of alternative donors showing more haploidentical
donors but fewer cord blood transplants. Bone Marrow Transplant.
50:476–482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Svahn BM, Remberger M, Myrback KE,
Holmberg K, Eriksson B, Hentschke P, Aschan J, Barkholt L and
Ringdén O: Home care during the pancytopenic phase after allogeneic
hematopoietic stem cell transplantation is advantageous compared
with hospital care. Blood. 100:4317–4324. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ringden O, Remberger M, Holmberg K,
Edeskog C, Wikstrom M, Eriksson B, Finnbogadottir S, Fransson K,
Milovsavljevic R, Omazic B, et al: Many days at home during
neutropenia after allogeneic hematopoietic stem cell
transplantation correlates with low incidence of acute
graft-versus-host disease. Biol Blood Marrow Transplant.
19:314–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ringdén O, Remberger M, Törlén J, Engström
M, Fjaertoft G, Mattsson J and Svahn BM: Home care during
neutropenia after allogeneic hematopoietic stem cell
transplantation in children and adolescents is safe and may be more
advantageous than isolation in hospital. Pediatr Transplant.
18:398–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
European Group of Bone Marrow
Transplantation, . Indicatios for allogeneic HSTC. https://www.ebmt.orgAccessed on. April 12–2016.
|
|
9
|
Apperley J, Carreras E, Gluckman E and
Masszi T: ESH-EBMT Handbook on Haemopoietic Stem Cell
Transplantation. 6th. European School of Haematology; 2012
|
|
10
|
Schaffer M, Aldener-Cannava A, Remberger
M, Ringden O and Olerup O: Roles of HLA-B, HLA-C and HLA-DPA1
incompatibilities in the outcome of unrelated stem-cell
transplantation. Tissue Antigens. 62:243–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Latham K, Little AM and Madrigal JA: An
overview of HLA typing for hematopoietic stem cell transplantation.
Methods Mol Biol. 1109:73–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ringden O, Schaffer M, Le Blanc K, Persson
U, Hauzenberger D, Abedi MR, Olerup O, Ljungman P and Remberger M:
Which donor should be chosen for hematopoietic stem cell
transplantation among unrelated HLA-A, -B, and -DRB1 genomically
identical volunteers? Biol Blood Marrow Transplant. 10:128–134.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakasone H, Remberger M, Tian L, Brodin P,
Sahaf B, Wu F, Mattsson J, Lowsky R, Negrin R, Miklos DB, et al:
Risks and benefits of sex-mismatched hematopoietic cell
transplantation differ according to conditioning strategy.
Haematologica. 100:1477–1485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gratwohl A: The EBMT risk score. Bone
Marrow Transplant. 47:749–756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hauzenberger D, Schaffer M, Ringdén O,
Hassan Z, Omazic B, Mattsson J, Wikström AC and Remberger M:
Outcome of haematopoietic stem cell transplantation in patients
transplanted with matched unrelated donors vs allele-mismatched
donors: a single centre study. Tissue Antigens. 72:549–558. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ringden O, Erkers T, Aschan J,
Garming-Legert K, Le Blanc K, Hagglund H, Omazic B, Svenberg P,
Dahllöf G, Mattsson J, et al: A prospective randomized toxicity
study to compare reduced-intensity and myeloablative conditioning
in patients with myeloid leukaemia undergoing allogeneic
haematopoietic stem cell transplantation. J Intern Med.
274:153–162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uzunel M, Remberger M, Sairafi D, Hassan
Z, Mattsson J, Omazic B, Barkholt L and Ringdén O: Unrelated versus
related allogeneic stem cell transplantation after reduced
intensity conditioning. Transplantation. 82:913–919. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ringden O, Karlsson H, Olsson R, Omazic B
and Uhlin M: The allogeneic graft-versus-cancer effect. Br J
Haematol. 147:614–633. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sandmaier BM, Mackinnon S and Childs RW:
Reduced intensity conditioning for allogeneic hematopoietic cell
transplantation: current perspectives. Biol Blood Marrow
Transplant. 13:(Suppl 1). 87–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Griffith LM, McCoy JP Jr, Bolan CD,
Stroncek DF, Pickett AC, Linton GF, Lundqvist A, Srinivasan R,
Leitman SF and Childs RW: Persistence of recipient plasma cells and
anti-donor isohaemagglutinins in patients with delayed donor
erythropoiesis after major ABO incompatible non-myeloablative
haematopoietic cell transplantation. Br J Haematol. 128:668–675.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Remberger M, Svahn BM, Mattsson J and
Ringdén O: Dose study of thymoglobulin during conditioning for
unrelated donor allogeneic stem-cell transplantation.
Transplantation. 78:122–127. 2004.PubMed/NCBI
|
|
22
|
Storb R, Kolb HJ, Deeg HJ, Weiden PL,
Appelbaum F, Graham TC and Thomas ED: Prevention of
graft-versus-host disease by immunosuppressive agents after
transplantation of DLA-nonidentical canine marrow. Bone Marrow
Transplant. 1:167–177. 1986.PubMed/NCBI
|
|
23
|
Futrega K, Lott WB and Doran MR: Direct
bone marrow HSC transplantation enhances local engraftment at the
expense of systemic engraftment in NSG mice. Sci Rep. 6:238862016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stikvoort A, Gertow J, Sundin M, Remberger
M, Mattsson J and Uhlin M: Chimerism patterns of long-term stable
mixed chimeras posthematopoietic stem cell transplantation in
patients with nonmalignant diseases: follow-up of long-term stable
mixed chimerism patients. Biol Blood Marrow Transplant. 19:838–844.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liesveld JL and Rothberg PG: Mixed
chimerism in SCT: conflict or peaceful coexistence? Bone Marrow
Transplant. 42:297–310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mattsson J, Uzunel M, Tammik L, Aschan J
and Ringden O: Leukemia lineage-specific chimerism analysis is a
sensitive predictor of relapse in patients with acute myeloid
leukemia and myelodysplastic syndrome after allogeneic stem cell
transplantation. Leukemia. 15:1976–1985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ringdén O, Okas M, Uhlin M, Uzunel M,
Remberger M and Mattsson J: Unrelated cord blood and mismatched
unrelated volunteer donor transplants, two alternatives in patients
who lack an HLA-identical donor. Bone Marrow Transplant.
42:643–648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seggewiss R and Einsele H: Immune
reconstitution after allogeneic transplantation and expanding
options for immunomodulation: an update. Blood. 115:3861–3868.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bosch M, Khan FM and Storek J: Immune
reconstitution after hematopoietic cell transplantation. Curr Opin
Hematol. 19:324–335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Storek J, Geddes M, Khan F, Huard B, Helg
C, Chalandon Y, Passweg J and Roosnek E: Reconstitution of the
immune system after hematopoietic stem cell transplantation in
humans. Semin Immunopathol. 30:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Podgorny PJ, Pratt LM, Liu Y,
Dharmani-Khan P, Luider J, Auer-Grzesiak I, Mansoor A, Williamson
TS, Ugarte-Torres A, Hoegh-Petersen M, et al: Low counts of B
cells, natural killer cells, monocytes, dendritic cells, basophils,
and eosinophils are associated with postengraftment infections
after allogeneic hematopoietic cell transplantation. Biol Blood
Marrow Transplant. 22:37–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Remberger M, Ackefors M, Berglund S,
Blennow O, Dahllöf G, Dlugosz A, Garming-Legert K, Gertow J,
Gustafsson B, Hassan M, et al: Improved survival after allogeneic
hematopoietic stem cell transplantation in recent years. a
single-center study. Biol Blood Marrow Transplant. 17:1688–1697.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blennow O, Ljungman P, Sparrelid E,
Mattsson J and Remberger M: Incidence, risk factors, and outcome of
bloodstream infections during the pre-engraftment phase in 521
allogeneic hematopoietic stem cell transplantations. Transpl Infect
Dis. 16:106–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sairafi D, Mattsson J, Uhlin M and Uzunel
M: Thymic function after allogeneic stem cell transplantation is
dependent on graft source and predictive of long term survival.
Clin Immunol. 142:343–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Remberger M, Ringdén O and Mattsson J:
Bone marrow aspiration technique has deteriorated in recent years.
Bone Marrow Transplant. 50:1007–1009. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Holtick U, Albrecht M, Chemnitz JM,
Theurich S, Skoetz N, Scheid C and von Bergwelt-Baildon M: Bone
marrow versus peripheral blood allogeneic haematopoietic stem cell
transplantation for haematological malignancies in adults. Cochrane
Database Syst Rev. 4:CD0101892014.
|
|
37
|
Wu S, Zhang C, Zhang X, Xu YQ and Deng TX:
Is peripheral blood or bone marrow a better source of stem cells
for transplantation in cases of HLA-matched unrelated donors? a
meta-analysis. Crit Rev Oncol Hematol. 96:20–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chevallier P, Robillard N, Illiaquer M,
Esbelin J, Mohty M, Bodin-Bressollette C, Guillaume T, Stocco V,
Auffray F, Derenne S, et al: Characterization of various blood and
graft sources: a prospective series. Transfusion. 53:2020–2026.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deotare U, Al-Dawsari G, Couban S and
Lipton JH: G-CSF-primed bone marrow as a source of stem cells for
allografting: revisiting the concept. Bone Marrow Transplant.
50:1150–1156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lundqvist A, Smith AL, Takahashi Y, Wong
S, Bahceci E, Cook L, Ramos C, Tawab A, McCoy JP Jr, Read EJ, et
al: Differences in the phenotype, cytokine gene expression
profiles, and in vivo alloreactivity of T cells mobilized
with plerixafor compared with G-CSF. J Immunol. 191:6241–6249.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Saraceni F, Shem-Tov N, Olivieri A and
Nagler A: Mobilized peripheral blood grafts include more than
hematopoietic stem cells: the immunological perspective. Bone
Marrow Transplant. 50:886–891. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rubinstein P, Dobrila L, Rosenfield RE,
Adamson JW, Migliaccio G, Migliaccio AR, Taylor PE and Stevens CE:
Processing and cryopreservation of placental/umbilical cord blood
for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA.
92:10119–10122. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ballen KK, Gluckman E and Broxmeyer HE:
Umbilical cord blood transplantation: the first 25 years and
beyond. Blood. 122:491–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
